{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:03:32Z","timestamp":1772816612719,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T16:37:44Z","timestamp":1715099864000},"page":"642-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg\/m2 versus 140 mg\/m2"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5542-7799","authenticated-orcid":false,"given":"Zachary","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Campbell","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramses","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Jillella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-3975","authenticated-orcid":false,"given":"Amany R.","family":"Keruakous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-9087","authenticated-orcid":false,"given":"Amber B.","family":"Clemmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2024.05.005_bib0001","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13608","article-title":"Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma","volume":"171","author":"Auner","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.05.005_bib0002","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies\u2014Current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.clml.2024.05.005_bib0003","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.05.005_bib0004","first-page":"501","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"BMT."},{"issue":"7","key":"10.1016\/j.clml.2024.05.005_bib0005","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s00277-020-04378-8","article-title":"Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a fenchmark for experimental therapies","volume":"100","author":"Gordillo","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.05.005_bib0006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years: auto-sct in elderly multiple myeloma patients","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.05.005_bib0007","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.bbmt.2018.12.094","article-title":"Reduced-dose melphalan (140 or 100 mg\/m2) maintains efficacy and tolerability for multiple myeloma patients with advanced age or renal impairment undergoing auto-hct","volume":"25","author":"Ngo","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2024.05.005_bib0008","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtct.2022.06.013","article-title":"High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Ali","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2024.05.005_bib0009","first-page":"1616","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra","year":"2017","journal-title":"BMT."},{"issue":"7","key":"10.1016\/j.clml.2024.05.005_bib0010","first-page":"1029","article-title":"Melphalan dose in myeloma patients \u226565 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study","volume":"54","author":"Ghilardi","year":"2019","journal-title":"BMT."},{"key":"10.1016\/j.clml.2024.05.005_bib0011","unstructured":"American Society of Transplant and Cellular Therapy \u2013 Pharmacy special interest group. Principles of chemotherapeutics in HCT. Fundamentals Backbones for HCT Training Course E-Book. 2021. 68-118."},{"key":"10.1016\/j.clml.2024.05.005_bib0012","unstructured":"National Comprehensive Cancer Network, Inc Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for multiple myeloma V.1.2023.. 2022. Accessed September 28, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"3","key":"10.1016\/j.clml.2024.05.005_bib0013","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m2 or 200 mg\/m2 for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.05.005_bib0014","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure: autologous transplant in myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:27:36Z","timestamp":1724473656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001770"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg\/m2 versus 140 mg\/m2","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}